Kelly Foster

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates

James W. Purcell, Sonia G. Tanlimco, Jonathan A. Hickson et al. · Cancer Research · 2018 · 199 citations

Medicine, Cancer Biology, Oncology +17

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Scott Ackler, Michael J. Mitten, Kelly Foster et al. · Cancer Chemotherapy and Pharmacology · 2010 · 121 citations

Medicine, Hematology, Oncology +12

ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>

Scott Ackler, Xiao Yu, Michael J. Mitten et al. · Molecular Cancer Therapeutics · 2008 · 73 citations

Medicine, Oncology, Pharmacology +13

Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin

Jonathan A. Hickson, Scott Ackler, Dieter H. Klaubert et al. · Cell Death and Differentiation · 2010 · 64 citations · Full text

Life Sciences, Biophysics, Cell Biology +13

Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours <i>in vivo</i>

Scott Ackler, MJ Mitten, J Chen et al. · British Journal of Pharmacology · 2012 · 39 citations · Full text

Medicine, Oncology, Pharmacology +12